Question 1

What is Apalutamide?

Accepted Answer

Apalutamide is a Other.

Question 2

How often does Apalutamide appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Apalutamide first tracked by Ergen?

Accepted Answer

First tracked on May 31, 2026.

Question 4

When was Apalutamide last mentioned in news?

Accepted Answer

Last active on Jun 02, 2026.

Question 5

What is Apalutamide's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Apalutamide in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Apalutamide?

Accepted Answer

J&J Erleada improves prostate cancer outcomes (May 31, 2026, 6 articles).

Question 8

How did the "J&J Erleada improves prostate cancer outcomes" event impact Apalutamide?

Accepted Answer

Apalutamide, a drug by Johnson & Johnson>>>, demonstrated improved efficacy in treating high-risk localized prostate cancer, leading to potential global regulatory approvals and increased usage.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.